Surgery Today

, Volume 37, Issue 11, pp 923–943

UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction

  • Fumihiro Tanaka
Review Article

DOI: 10.1007/s00595-007-3578-5

Cite this article as:
Tanaka, F. Surg Today (2007) 37: 923. doi:10.1007/s00595-007-3578-5


UFT (tegafur and uracil) is an oral anticancer drug that has been developed in Japan. Owing to its mild toxicity profile, UFT can be suitable in an adjuvant setting following a complete tumor resection, whereas its direct antitumor effect achieved may be insufficient for advanced unresectable disease. Therefore, a variety of adjuvant chemotherapy trials with UFT have been conducted, and results of well-designed randomized controlled trials have recently shown a survival benefit of postoperative UFT treatment in resected lung, gastric, colorectal, and breast cancer. In the present article, postoperative adjuvant trials with UFT-containing chemotherapy are reviewed, and the mechanism of action and future directions are also discussed.

Key words

Tegafur Uracil UFT Solid tumor Adjuvant chemotherapy 

Copyright information

© Springer-Verlag Tokyo 2007

Authors and Affiliations

  • Fumihiro Tanaka
    • 1
  1. 1.Department of Thoracic SurgeryHyogo College of MedicineNishinomiyaJapan

Personalised recommendations